The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
The number of patients with chronic heart failure syndrome is steadily increasing worldwide and Ukraine is not an exception. About 50 % of patients with heart failure have preserved ejection fraction of left ventricle. Recently, there has been significant progress in the diagnosis of this phenotype...
Saved in:
| Main Authors: | M. Yu. Kolesnyk, Ya. Yu. Maistrovych |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2024-03-01
|
| Series: | Сучасні медичні технології |
| Subjects: | |
| Online Access: | https://medtech.mphu.edu.ua/article/view/296545/292789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01) -
Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01) -
Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
by: Miloud Cherbi, et al.
Published: (2025-04-01) -
Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
by: Arunmanakul P, et al.
Published: (2025-02-01) -
Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
by: Lucie Maigret, et al.
Published: (2025-03-01)